A Phase 2 interventional study of Cromolyn Sodium (34.2 mg BID) and Cromolyn Sodium (17.1 mg BID) in Amyotrophic Lateral Sclerosis (ALS), sponsored by PhenoNet, Inc.. Recruiting at 22 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by PhenoNet, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain — 11 open to participants now, 16 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · Spain.
Among the 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain, this one is the 30th largest by planned enrollment of the 51 interventional ones that give a count, is one of 4 that started in 2025, is one of 13 in phase 2, reaches primary completion later than 7 of the 15 other live ones, and was the 50th registered.
980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →11 of the 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Spain, Belgium, Canada and 2 more countries
Ages 18–80
Eli Lilly and Company · Sites in Spain, Belgium, Canada and 2 more countries
Ages 18–80
Prilenia · Sites in Spain, United States, Belgium and 10 more countries
Ages 18–80
Biogipuzkoa Health Research Institute · Sites in Spain
Ages 18–75
Zydus Therapeutics Inc. · Sites in Spain, United States, Australia and 9 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 19 · Phase 3 24
First in 2007; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 105 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 227 across the 51 interventional studies, 60 across the 5 observational. Of the 37 that completed or were terminated, 20 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 56 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with PhenoNet, Inc. as lead sponsor.
PhenoNet, Inc. has 1 study filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
4 of the studies in Amyotrophic Lateral Sclerosis with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04856982Phase 3BiogenStudy to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | 2027-08-07 |
| NCT07414212Biogipuzkoa Health Research InstituteEvaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS) | 2026-11-25 |
| NCT07142291PhenoNet, Inc.PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS | 2027-03 |
| NCT07100119Eli Lilly and CompanyA Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to test the effects of PHENOGENE-1A, which is the treatment under investigation in this study. This research will investigate if PHENOGENE-1A can help people with ALS by measuring their function using the ALS Functional Rating Scale Revised (ALSFRS-R), measuring lung function using pulmonary function tests (PFTs), such as forced vital capacity (FVC), and measuring neuro-inflammatory biomarkers in the blood.
This is a Phase IIB, randomized, double-blind, placebo-controlled study designed to assess the effects of PHENOGENE-1A (oral inhalation via dry powder inhaler [DPI]) in subjects with mild to moderate ALS disease. Eligible subjects will be randomized to receive either low dose PHENOGENE-1A (34.2 mg per day: in 2 doses of 17.1 mg and matching placebo BID), high dose PHENOGENE-1A (68.4 mg per day: 34.2 mg BID), or placebo (2 matching placebo capsules BID) (see table below), in a 2:2:1 ratio. Subjects will receive treatment for a duration of 24 weeks. All subjects must be on a stable dose of Riluzole 50 mg BID (100 mg daily) for at least 4 weeks prior to randomization and must continue their Riluzole regimen, 50 mg BID (100 mg daily), as standard-of-care treatment, throughout the 24 week treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of ALS; the diagnosis of ALS defined by revised El Escorial criteria as follows:
Female subjects who are of must agree to use of highly effective methods of consistent with local regulations during the study, and for 3 months after the study drug administration. Examples include the following, but not limited to:
(Male subject should be willing to not donate sperm during the trial and for 3 months after the last dose of the study drug.)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
17.1 mg, BID, oral inhalation via dry powder inhaler
Drug: Cromolyn Sodium (17.1 mg BID) · Drug: Riluzole (100 mg)
34.2 mg, BID, oral inhalation via dry powder inhaler
Drug: Cromolyn Sodium (34.2 mg BID) · Drug: Riluzole (100 mg)
Placebo comparator matched to active treatment, BID, oral inhalation via dry powder inhaler
Drug: Placebo · Drug: Riluzole (100 mg)
17.1 mg, BID, oral inhalation
Also known as: Cromolyn, Sodium Cromoglycate
34.2 mg, BID, oral inhalation via dry powder inhaler
Also known as: Cromolyn, Sodium Cromoglycate, PHENOGENE-1A
Placebo comparator matched to active treatment.
50 mg, oral tablet, BID, standard of care treatment
Also known as: Rilutek
Absolute change in ALSFRS-R total score from baseline to Week 24
To evaluate the effects of PHENOGENE-1A (cromolyn) on functional changes in subjects with mild to moderate ALS using the ALS Functional Rating Scale-Revised (ALSFRS-R).
Time frame: Baseline to Week 24
Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
To evaluate the safety of PHENOGENE-1A following 24 weeks of twice daily (BID) treatment.
Time frame: Baseline to Week 24
Mean rank for CAFS at Week 24
To evaluate the effects of PHENOGENE-1A on function and survival using the Combined Assessment of Function and Survival (CAFS).
Time frame: Baseline to Week 24
Time to event requiring full-time or nearly full-time respiratory support
Time from randomization to the first of 7 consecutive days on which permanent assisted ventilation (invasive or non-invasive) was used for \>22 hours/day due to ALS progression.
Time frame: Randomization to Week 24
Mean change in percent predicted forced vital capacity (%FVC) from baseline to Week 24
To evaluate the effect of PHENOGENE-1A on respiratory changes.
Time frame: Baseline to Week 24
Mean change in peak inspiratory flow rate (PIFR) from baseline to Week 24
To evaluate changes in PIFR (L/min) during treatment.
Time frame: Baseline to Week 24
Absolute Values and Changes From Baseline in Vital Signs From Baseline to Week 24 by Treatment Arm
Vital signs will include: * Systolic blood pressure (mmHg) * Diastolic blood pressure (mmHg) * Pulse rate (beats per minute) * Respiratory rate (breaths per minute) * Body temperature (°C or °F, as recorded) Results will be summarized as: * Absolute values for each parameter at each scheduled visit. * Changes from baseline at each visit. * Summaries will be presented separately by treatment arm.
Time frame: Baseline to Week 24
Number and Percentage of Subjects With Abnormal Clinical Laboratory Values and Changes From Baseline to Week 24 by Treatment Arm
Safety laboratory assessments will include hematology, clinical chemistry, coagulation, and urinalysis panels. Each laboratory result will be classified as normal, abnormal (not clinically significant), or abnormal (clinically significant). Results will be summarized as: Number and percentage of subjects with abnormal laboratory values at each post-baseline visit, by treatment arm. Summary statistics for absolute values and changes from baseline at each visit.
Time frame: Baseline to Week 24
Number and Percentage of Subjects With Abnormal Physical Examination Findings From Baseline to Week 24 by Treatment Arm
The physical examination will assess head/neck, eyes, ears, nose/throat, cardiovascular, respiratory, abdominal, musculoskeletal, extremities, and skin systems. Each system will be classified as normal, abnormal (not clinically significant), or abnormal (clinically significant). Results will be summarized as the number and percentage of subjects with abnormal findings at each post-baseline visit.
Time frame: Baseline to Week 24
Number and Percentage of Subjects With Abnormal Neurological Examination Findings From Baseline to Week 24 by Treatment Arm
The neurological examination will assess mental status, motor function, sensory function, reflexes, and coordination/cerebellar function. Each domain will be classified as normal, abnormal (not clinically significant), or abnormal (clinically significant). Results will be summarized as the number and percentage of subjects with abnormal findings at each post-baseline visit.
Time frame: Baseline to Week 24
Number and Percentage of Subjects With Abnormal Electrocardiogram (ECG) Findings From Baseline to Week 24 by Treatment Arm
Standard 12-lead ECGs will be performed at protocol-specified visits. Parameters assessed will include: * Heart rate: 60-100 beats per minute (bpm) * PR interval: 120-200 milliseconds (ms) * QRS duration: 70-110 ms * QT interval: \< 440 ms in men, \< 460 ms in women * Corrected QT interval (QTcF, Fridericia's formula): \< 450 ms in men, \< 470 ms in women Each ECG result will be classified by the investigator as normal, abnormal (not clinically significant), or abnormal (clinically significant), using these ranges as reference. Results will be summarized as the number and percentage of subjects with abnormal ECG findings at each post-baseline visit.
Time frame: Baseline to Week 24
Number and Percentage of Subjects With Suicidal Ideation, Suicidal Behavior, or Self-Injurious Behavior Without Suicidal Intent on the Columbia Suicide Severity Rating Scale (C-SSRS) From Baseline to Week 24 by Treatment Arm
The Columbia Suicide Severity Rating Scale (C-SSRS) will be administered at protocol-specified visits to assess suicidal ideation, suicidal behavior, and self-injurious behavior without suicidal intent. * Suicidal ideation will be captured using categories 1-5 of the C-SSRS (ranging from passive wish to be dead to active suicidal ideation with plan and intent). * Suicidal behavior will be captured using categories 6-10 of the C-SSRS (preparatory acts, aborted attempts, interrupted attempts, and actual attempts). * Self-injurious behavior without suicidal intent will be reported separately. Results will be summarized as: Number and percentage of subjects with suicidal ideation, suicidal behavior, and self-injurious behavior without suicidal intent, compared between active treatment and placebo arms.
Time frame: Baseline to Week 24
Number and Percentage of Subjects Who Discontinue Study Participation Due to Adverse Events From Baseline to Week 24
The incidence of study discontinuation attributed to treatment-emergent adverse events (TEAEs) will be assessed. Results will be summarized as the number and percentage of subjects who withdraw from the study due to an adverse event, presented separately by treatment arm.
Time frame: Baseline to Week 24
Change in plasma neuroinflammatory biomarkers from baseline to Week 24
To evaluate the impact of two different doses of PHENOGENE-1A on neuroinflammation.
Time frame: Baseline (pre-dose) to Week 24
Plan to share: Undecided
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Mar 2027, 16 months after the start.
Of 36 industry-sponsored phase 2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's planned 16 months is below that.
Counting every sponsor, half of 73 studies reached it within 24 months; a quarter within 16 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cromolyn
Amyotrophic Lateral Sclerosis →